Fibroblast Activation Protein Alpha (FAP) Expression Is Associated with Disease Recurrence and Poor Response to Tyrosine Kinase Inhibitors in Advanced Clear Cell Renal Cell Carcinoma
Guardado en:
| Publicado en: | International Journal of Molecular Sciences vol. 26, no. 22 (2025), p. 11112-11127 |
|---|---|
| Autor principal: | |
| Otros Autores: | , , , , , , , , , , |
| Publicado: |
MDPI AG
|
| Materias: | |
| Acceso en línea: | Citation/Abstract Full Text + Graphics Full Text - PDF |
| Etiquetas: |
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
MARC
| LEADER | 00000nab a2200000uu 4500 | ||
|---|---|---|---|
| 001 | 3275535106 | ||
| 003 | UK-CbPIL | ||
| 022 | |a 1661-6596 | ||
| 022 | |a 1422-0067 | ||
| 024 | 7 | |a 10.3390/ijms262211112 |2 doi | |
| 035 | |a 3275535106 | ||
| 045 | 2 | |b d20251115 |b d20251130 | |
| 084 | |a 231645 |2 nlm | ||
| 100 | 1 | |a Riaza Montes María |u Department of Urology, Galdakao-Usansolo University Hospital, 48960 Usansolo, Spain; maria.riazamontes@osakidetza.eus | |
| 245 | 1 | |a Fibroblast Activation Protein Alpha (FAP) Expression Is Associated with Disease Recurrence and Poor Response to Tyrosine Kinase Inhibitors in Advanced Clear Cell Renal Cell Carcinoma | |
| 260 | |b MDPI AG |c 2025 | ||
| 513 | |a Journal Article | ||
| 520 | 3 | |a Despite advances in the management of advanced clear cell renal cell carcinoma (ccRCC), robust biomarkers for prognosis and therapeutic response prediction remain elusive. Fibroblast activation protein-α (FAP), a marker of activated cancer-associated fibroblasts (CAFs), has emerged as a potential indicator of tumor aggressiveness and resistance to systemic therapies in various solid tumors. This study evaluated the clinical relevance of stromal FAP expression in a cohort of 137 patients with advanced ccRCC and long-term follow-up. FAP immunohistochemistry (IHC) was performed on primary tumor specimens and correlated with key clinicopathological features, disease-free survival (DFS), overall survival (OS), and radiological response to first-line tyrosine kinase inhibitors (TKIs). A significantly higher percentage of FAP-positive CAFs was observed in primary tumors with high histological grade, extensive local invasion (pT3–4), and advanced clinical stage (NCCN stage III–IV). Stromal FAP expression was associated with shorter DFS and OS. Moreover, tumors lacking FAP expression were more likely to achieve complete response to TKI therapy as defined by RECIST criteria. These findings highlight the potential of FAP IHC as a prognostic and predictive tool in advanced ccRCC and support further clinical validation. | |
| 653 | |a Patients | ||
| 653 | |a Biomarkers | ||
| 653 | |a Kidney cancer | ||
| 653 | |a Medical prognosis | ||
| 653 | |a Metastasis | ||
| 653 | |a Fibroblasts | ||
| 653 | |a Tumors | ||
| 653 | |a Kinases | ||
| 653 | |a Lymphatic system | ||
| 653 | |a Proteins | ||
| 653 | |a Classification | ||
| 700 | 1 | |a Suárez Beatriz |u Department of Nursing, Faculty of Medicine and Nursing, University of the Basque Country (UPV/EHU), 48940 Leioa, Spain; beatriz.suarez@ehu.eus | |
| 700 | 1 | |a Solano-Iturri Jon Danel |u Biobizkaia Health Research Institute, 48903 Barakaldo, Spain; jondanel.solanoiturri@osakidetza.eus (J.D.S.-I.); carolineelisabeth.nunes-xavier@bio-bizkaia.eus (C.E.N.-X.); rpulidomurillo@gmail.com (R.P.); jilpath@gmail.com (J.I.L.) | |
| 700 | 1 | |a Lecumberri, David |u Department of Urology, Cruces University Hospital, 48903 Barakaldo, Spain; david.lecumberricastanos@osakidetza.eus (D.L.); anemiren.iturreguidelpozo@osakidetza.eus (A.M.I.) | |
| 700 | 1 | |a Iturregui, Ane Miren |u Department of Urology, Cruces University Hospital, 48903 Barakaldo, Spain; david.lecumberricastanos@osakidetza.eus (D.L.); anemiren.iturreguidelpozo@osakidetza.eus (A.M.I.) | |
| 700 | 1 | |a Lawrie, Charles H |u Molecular Oncology Group, Biogipuzkoa Health Research Institute, 20014 San Sebastián, Spain; charles.lawrie@bio-gipuzkoa.eus (C.H.L.); maria.armestoalvarez@bio-gipuzkoa.eus (M.A.) | |
| 700 | 1 | |a Armesto María |u Molecular Oncology Group, Biogipuzkoa Health Research Institute, 20014 San Sebastián, Spain; charles.lawrie@bio-gipuzkoa.eus (C.H.L.); maria.armestoalvarez@bio-gipuzkoa.eus (M.A.) | |
| 700 | 1 | |a Nunes-Xavier, Caroline E |u Biobizkaia Health Research Institute, 48903 Barakaldo, Spain; jondanel.solanoiturri@osakidetza.eus (J.D.S.-I.); carolineelisabeth.nunes-xavier@bio-bizkaia.eus (C.E.N.-X.); rpulidomurillo@gmail.com (R.P.); jilpath@gmail.com (J.I.L.) | |
| 700 | 1 | |a Pulido, Rafael |u Biobizkaia Health Research Institute, 48903 Barakaldo, Spain; jondanel.solanoiturri@osakidetza.eus (J.D.S.-I.); carolineelisabeth.nunes-xavier@bio-bizkaia.eus (C.E.N.-X.); rpulidomurillo@gmail.com (R.P.); jilpath@gmail.com (J.I.L.) | |
| 700 | 1 | |a López, José I |u Biobizkaia Health Research Institute, 48903 Barakaldo, Spain; jondanel.solanoiturri@osakidetza.eus (J.D.S.-I.); carolineelisabeth.nunes-xavier@bio-bizkaia.eus (C.E.N.-X.); rpulidomurillo@gmail.com (R.P.); jilpath@gmail.com (J.I.L.) | |
| 700 | 1 | |a Angulo, Javier C |u <label>11</label>Department of Urology, Hospital Universitario de Getafe, 28907 Getafe, Spain; javier.angulo@salud.madrid.org | |
| 700 | 1 | |a Larrinaga Gorka |u Biobizkaia Health Research Institute, 48903 Barakaldo, Spain; jondanel.solanoiturri@osakidetza.eus (J.D.S.-I.); carolineelisabeth.nunes-xavier@bio-bizkaia.eus (C.E.N.-X.); rpulidomurillo@gmail.com (R.P.); jilpath@gmail.com (J.I.L.) | |
| 773 | 0 | |t International Journal of Molecular Sciences |g vol. 26, no. 22 (2025), p. 11112-11127 | |
| 786 | 0 | |d ProQuest |t Health & Medical Collection | |
| 856 | 4 | 1 | |3 Citation/Abstract |u https://www.proquest.com/docview/3275535106/abstract/embedded/7BTGNMKEMPT1V9Z2?source=fedsrch |
| 856 | 4 | 0 | |3 Full Text + Graphics |u https://www.proquest.com/docview/3275535106/fulltextwithgraphics/embedded/7BTGNMKEMPT1V9Z2?source=fedsrch |
| 856 | 4 | 0 | |3 Full Text - PDF |u https://www.proquest.com/docview/3275535106/fulltextPDF/embedded/7BTGNMKEMPT1V9Z2?source=fedsrch |